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Summary 
Endogenous regulators, such as, angiotensin-II (AngII), endothelin-1 (ET-1) and 
urotensin-II (U-II) are released from various cells-types and their plasma levels are 
elevated in several cardiovascular diseases. The present study evaluated a potential 
crosstalk between these systems by investigating if the myocardial effects of U-II are 
modulated by AngII or ET-1. 
Effects of U-II (10-8, 10-7, 10-6M) were tested in rabbit papillary muscles in the absence 
and in the presence of losartan (selective AT1 receptor antagonist), PD-145065 
(nonselective ET-1 receptors antagonist), losartan plus PD-145065, AngII or ET-1. 
U-II promoted concentration-dependent negative inotropic and lusitropic effects that 
were abolished in all experimental conditions. Also, U-II increased resting muscle 
length up to 1.008±0.002 L/Lmax. Correcting it to its initial value resulted in a 
19.5±3.5% decrease of resting tension, indicating increased muscle distensibility. This 
effect on muscle length was completely abolished in the presence of losartan and 
significantly attenuated by PD-145065 or losartan plus PD-145065. This effect was 
increased in the presence of AngII, in which condition resting tension decrease 
27.5±3.9%, but was unaffected by the presence of ET-1. 
This study demonstrated an interaction of the U-II system with the AngII and ET-1 
systems in terms of regulation of systolic and diastolic function. 
 
Key words: Urotensin II; Angiotensin II; Endothelin-1, cardiac function; myocardial 
distensibility 
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INTRODUCTION 
Urotensin II (U-II) is a vasoactive cyclic peptide that was originally isolated 
from fish urophysis and has been cloned from humans since 1998 (Coulouarn et al. 
1998). UII has been identified as the endogenous ligand for the orphan G protein-
coupled receptor, GPR14 (U-II receptor, UT) (Ames et al. 1999; Douglas et al. 2002). 
Both U-II and its receptor are expressed in the mammalian cardiovascular system 
namely in the myocardium, vascular smooth muscle cells and endothelial cells (Johns et 
al. 2004; Egginger et al. 2006). Human U-II (hU-II) effectively constricts isolated 
arteries from non-human primates. The potency of vasoconstriction is of a greater 
magnitude than that of endothelin 1 (ET-1), making U-II the most potent mammalian 
vasoconstrictor (Ames et al. 1999). 
Furthermore, U-II was reported to affect the process of cell growth in the heart. 
This peptide exerted mitogenic effects on vascular smooth muscle cells (Sauzeau et al. 
2001; Watanabe et al. 2001a;b) and human endothelial cells (Shi et al. 2006), induced 
collagen and fibronectin synthesis by cardiac fibroblasts, and caused cardiomyocyte 
hypertrophy (Tzanidis et al. 2003; Johns et al. 2004; Russell 2004). Thereby, U-II 
contributes to ventricular remodeling and deterioration of systolic and diastolic 
function, similarly to what has been described for other vasoconstrictor peptides such as 
angiotensin-II (AngII) and ET-1 (Weber et al. 1994; Ito 1997). 
Moreover, elevation of U-II in the plasma and hearts of patients with congestive 
heart failure has been observed, and these circulating levels were related to the 
functional class of the disease and correlated negatively with left ventricular ejection 
fraction (Douglas et al. 2002; Russell et al. 2003; Russell 2004; Gruson et al. 2006). 
Also, U-II correlated significantly with big-ET-1 and brain natriuretic peptide, 
suggesting that U-II could play a role in worsening the course of congestive heart failure 
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and is associated with established markers of cardiovascular dysfunction (Gruson et al. 
2006). 
Unlike the well-known role of chronically elevated U-II levels in progression to 
cardiac fibrosis and ventricular remodeling, the acute diastolic effects of U-II remain 
less explored. We previously found that AngII (Leite-Moreira et al. 2006), ET-1 (Leite-
Moreira et al. 2003) and U-II acutely increase myocardial distensibility. In the case of 
U-II this effect is mediated by UT receptor, NO and prostaglandins (Fontes-Sousa et al. 
2007). The intracellular signaling of U-II and its interaction with other vasoconstrictors 
such as AngII and ET-1 are poorly understood, although is has been established that U-
II shares some subcellular pathways and interacts with these vasoactive systems (Tasaki 
et al. 2004; Li et al. 2005; Wang et al. 2007). Although plausible, the crosstalk between 
U-II and AngII or ET-1 in the regulation of myocardial distensibility has not been 
studied yet. The main goal of the present study was therefore to test this hypothesis by 
investigating to what extent the myocardial effects of U-II are modulated by AngII or 
ET-1. 
 
METHODS 
The investigation conforms to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication Nº 85-23, 
Revised 1996). 
 
Experimental preparation 
Isometric and isotonic contractions were measured in papillary muscles isolated 
from the right ventricle of rabbits. Male New Zealand White rabbits (Oryctolagus 
cuniculus; 1.2–2.7 kg; n=32) were anesthetized with intravenous sodium pentobarbital 
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(25mgkg-1). A left thoracotomy was performed, and beating hearts were quickly excised 
and immersed in a modified Krebs-Ringer (KR) solution (composition in mM: 98 NaCl, 
4.7 KCl, 2.4 MgSO4.7H2O, 1.2 KH2PO4, 4.5 glucose, 1.8 CaCl2.2H2O, 17 NaHCO3, 15 
sodium pyruvate, 5 sodium acetate, 0.02 atenolol) at 35ºC with cardioplegic 2,3-
butanedione monoxime (BDM; 3%) and 5% Newborn Calf Serum. Atenolol was used 
to prevent β-adrenergic mediated effects. The solutions were in equilibrium with 95% 
O2 and 5% CO2, to obtain a pH between 7.38-7.42. 
The time from thoracotomy to dissection was ~3 min. The right ventricle was 
opened and papillary muscles were isolated by first dividing the chordae tendinae at the 
muscle tip and then freeing the muscle base and a small amount of surrounding 
myocardium from the ventricular wall. Only long, thin, uniformly cylindrical muscles 
were used. 
After dissection, papillary muscles (n=52; length: 4.6±0.2mm; weight: 
3.5±0.2mg; preload: 4.0±0.2mN) were mounted vertically in a 10ml plexi glass organ 
bath containing the aforementioned KR solution at 35ºC. The lower muscular end was 
fixed in a phosphorbronze clip, and the upper tendinous end was attached to an 
electromagnetic length–tension transducer (University of Antwerp, Belgium). 
Preload was initially estimated according to muscle dimensions. After 10 min, 
muscles were stimulated at interstimulus interval of 1670 ms and voltage of 10% above 
threshold by rectangular pulses of 5 ms duration through two platinum electrodes. 
Twenty minutes later, bathing solutions were replaced by corresponding KR solutions 
without BDM and the muscle started to contract. One hour later, bathing solution was 
replaced by corresponding serum-free KR solution. During the next 2 hours, the 
muscles were stabilized. Finally, the muscles were stretched to a muscle length at which 
active force development was maximal. This length (mm) is known as maximum 
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physiological length (Lmax). Protocols were initiated after obtaining two similar isotonic 
and isometric control twitches separated by a 10 min interval. 
At the end of the experiment the muscles were lightly blotted and then weighed. 
Muscle cross-sectional area was calculated by dividing the weight of the muscle by its 
length at Lmax. A cylindrical shape and a specific gravity of 1.0 were assumed. Muscle 
tension was then expressed as force normalized per cross-sectional area (mNmm-2). 
 
Experimental protocols 
The effects of increasing concentrations of hU-II (10-8, 10-7 and 10-6 M) on 
contraction, relaxation, and diastolic properties of the myocardium were studied in 
rabbit papillary muscles in the absence (n=12) or in the presence of (i) losartan (10-6 M; 
n=8), a selective AT1 receptor competitive antagonist, (ii) PD-145065 (C52H65N7O10; 
10-7 M; n=7), a nonselective antagonist of ET-1 receptors, (iii) losartan (10-6 M) plus 
PD-145065 (10-7 M) (n=8), (iv) AngII (10-5M; n=10), or (v) ET-1 (10-8M; n=7). These 
substances were dissolved in the KR solution before the addition of U-II, and muscle 
twitches were recorded after a stable response was obtained, typically 15-20min later. 
After that, U-II was added cumulatively without any washout between. 
Of note, that in each experimental protocol all papillary muscles were obtained 
from different animals. PD-145065 and hU-II were obtained from American Peptide 
Company (Sunnyvale, CA, USA) and Bachem (Bubendorf, Switzerland), respectively. 
All the other reagents were obtained from Sigma Chemical Co (St Louis, MO, USA). 
Peptides were prepared in aliquots and stored at -20 ºC. 
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Data acquisition and analysis 
Isotonic and isometric twitches were converted online to digital data with a 
sampling frequency of 1000 Hz (Daqbook/120, IOTech Inc. Cleveland, Ohio, USA) and 
analyzed with a dedicated software (University of Antwerp, Belgium). 
Selected parameters included: resting tension (RT; mNmm-2), active tension 
(AT; mNmm-2); maximal velocities of tension rise (dT/dtmax; mNmm-2s-1) and decline 
(dT/dtmin; mNmm-2s-1); peak isotonic shortening (PS; %Lmax); and maximal velocities of 
shortening (dL/dtmax; Lmaxs-1) and lengthening (dL/dtmin; Lmaxs-). 
In the various protocols, results are given as percent change from baseline. For 
the parameters that are expressed as negative values (e.g. dT/dtmin) such percent change 
refers to the absolute values. When the pharmacological inhibitors were used, the term 
baseline refers to the performance in the presence of those inhibitors, before the addition 
of U-II. 
 
Statistical methods 
Values are presented as means ± standard error of the mean (SEM) of n 
experiments. Effects of increasing concentrations of U-II alone on the different 
experimental parameters were analyzed by one-way repeated-measures ANOVA. 
Effects of increasing concentrations of U-II under various experimental conditions were 
analyzed with a repeated-measures two-way ANOVA. Effects on the various 
parameters of a single concentration of the antagonists were analyzed with a paired t-
test. When significant differences were detected with any of the ANOVA tests, the 
Student-Newman-Keuls test was selected to perform pairwise multiple comparisons. 
P<0.05 was accepted as significant. 
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RESULTS 
Baseline performance of rabbit papillary muscles was similar in all experimental 
protocols. Mean values of the contractile parameters from the 52 papillary muscles were 
as follows: AT 26.0±1.9 mN/mm2; dT/dtmax 190.4±15.6 mN/mm2·s; dT/dtmin -140.3±8.6 
mN/mm2·s; PS 15.3±0.9% of Lmax; dL/dtmax 1.17±0.07 Lmax.s-1; dL/dtmin -4.9±0.4 Lmax.s-
1. The presence of losartan, PD-145065, or losartan plus PD-145065 did not 
significantly modify per se any of the analysed contractile parameters. The presence of 
AngII and ET-1 significantly increased active tension by 7.2±2.1% and 31.7±4.9%, 
respectively. 
U-II induced concentration-dependent negative inotropic (AT, dT/dtmax) and 
lusitropic (dT/dtmin) effects (Fig. 1). The highest concentration of U-II (10-6 M) 
decreased 15.8±5.6% AT, 13.5±5.4% dT/dtmax, and 18.1±4.5% dT/dtmin. With regard to 
the diastolic properties of the myocardium, we observed that U-II progressively 
increased resting muscle length (Fig. 1) at a constant resting tension. Correcting, at the 
end of the experiment, muscle length to its initial value resulted in a 19.5±3.5% 
decrease of resting tension, without altering the other contractile parameters. These 
effects indicate an increase in muscle distensibility, or on the other hand, a decrease in 
muscle stiffness. 
In the presence of a nonselective endothelin ETA/ETB receptor antagonist 
(PD-145065), the negative inotropic (Fig. 2) and lusitropic effects of U-II were 
abolished. Similarly, losartan, a selective competitive AT1 receptor antagonist, or 
losartan plus PD-145065 completely abolished the negative inotropic (Fig. 2) and 
lusitropic effects of U-II. When added previously to the bath, AngII abolished the 
negative inotropic (Fig. 3) and lusitropic effects of U-II. In the presence of ET-1, U-II 
promoted a slightly positive inotropic (Fig. 3) and lusitropic effects. 
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The effects of U-II on myocardial distensibility were significantly attenuated by 
PD-145065 or PD-145065 plus losartan, leading to a decrease in passive tension of only 
11.6±2.7% and 9.9±3.5%, respectively (Fig. 2). On the other hand, in the presence of 
losartan the effects of U-II on passive muscle length and RT were no more statistically 
significant (Fig. 2). Finally, this effect was increased in the presence of AngII, in which 
condition resting tension decrease 27.5±3.9%, but was unaffected by the presence of 
ET-1 (Fig. 3). 
 
DISCUSSION 
In the present study we evaluated, in rabbit papillary muscles, the myocardial 
effects of U-II. We showed that U-II induced negative inotropic and lusitropic effects, 
as previously documented (Fontes-Sousa et al. 2007) and a significant concentration-
dependent acute increase of myocardial distensibility, or conversely, a decrease in 
myocardial stiffness. In the presence of a selective AT1 receptor antagonist (losartan), a 
nonselective antagonist of ET-1 receptors (PD-145065), or both, the negative inotropic 
effect of U-II (AT, dT/dtmax) was completely abolished. The same occurred in the 
presence of AngII, while with ET-1, U-II promoted a slightly positive inotropic effect. 
On the other hand, the effect of U-II on myocardial distensibility was dependent on AT1 
receptors, ETA and ETB receptors. Additionally, the presence of AngII potentiated this 
effect. 
The concentrations of U-II evaluated in the present study (10-8M-10-6M) were 
considerably higher than those observed in plasma of control subjects in vivo (average 
from 2-20 pmol/l) (Ng et al. 2002; Watanabe et al. 2006). These plasma concentrations 
are increased in several cardiovascular conditions such as hypertension (Cheung et al. 
2004), atherosclerosis (Suguro et al. 2007), coronary artery disease (Heringlake et al. 
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2004), and congestive heart failure (Richards et al. 2002). However, it is important to 
refer that reported human plasma U-II levels vary by ~1000- to 10,000-fold between 
groups/assays, which has been ascribed mainly to the methodology chosen for measure 
the plasma levels of U-II. Furthermore, as U-II might act predominantly in an 
autocrine/paracrine way, local concentrations are presumably several times higher than 
those present in the plasma. 
The role of U-II in cardiovascular physiology and pathology remains largely 
uncertain. Recent experimental and clinical studies have revealed increased expression 
of U-II and UT receptor in animals with experimentally induced heart failure and 
myocardial infarction and in patients with heart failure, hypertension, atherosclerosis, 
and diabetic nephropathy, suggesting a potential role of U-II in both cardiovascular and 
renal diseases (Zhu et al. 2006). On the other hand, in cardiovascular diseases, the 
expression of numerous neurohumoral factors such as AngII (Pfeffer and Braunwald 
1990), ET-1 (Best and Lerman 2000), catecholamines (Ueyama et al. 2003), 
thromboxane A2 (Miyahara et al. 1997), and serotonin (Levy 2006) has been shown to 
be up-regulated. These studies give rise to the hypothesis that the interaction between 
U-II and other vasoactive substances may be crucial in modulating the cardiovascular 
effects of U-II under a certain disease status. Crosstalk of intracellular signalling 
pathways is probably the underlying mechanism of the interaction between U-II and 
other vasoactive substances (Zhu et al. 2006). 
Both ET-1 and AngII receptor systems are coupled to phospholipase C-Gαq 
protein signaling pathways, resulting in activation of protein kinase C isoforms and 
inositol phosphates, and both systems induce pathological hypertrophy accompanied by 
contractile dysfunction and poor clinical outcomes (Braunwald and Bristow 2000). U-II 
shares similar biological activities and signaling pathways with these hypertrophic Gq-
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coupled receptor ligands, since it has been also observed the coupling of its receptor to 
activated protein kinase C-dependent pathways (Saetrum Opgaard et al. 2000; Russell 
and Molenaar 2004). 
The decrease of passive tension as the one promoted by U-II represents a 
potentially important adaptation mechanism, since it demonstrates that U-II might allow 
the ventricle to reach the same diastolic volume with almost 20% lower filling pressures 
(Fontes-Sousa et al. 2007). However, we must consider that a sustained increase in 
myocardial length, as the one induced by U-II, might contribute to ventricular dilatation, 
which is another important feature of ventricular remodeling. Also, the acute beneficial 
effects of U-II on diastolic function may be also overcome by its role in the promotion 
of cardiac fibrosis and hypertrophy (Bousette et al. 2006b). 
The present study showed that the increase of myocardial distensibility induced 
by U-II is dependent on Ang II and ET-1 systems. The results of the present study are in 
line with the ones of previous studies: the presence of losartan (a selective AT1 receptor 
competitive antagonist) or AngII, respectively abolished and potentiated the effects of 
U-II on myocardial distensibility. In fact, we have recently shown that the decrease of 
myocardial stiffness induced by AngII requires AT1 receptor activation (Leite-Moreira 
et al. 2006). On the other hand, although ET-1 also increases myocardial distensibility 
(Leite-Moreira et al. 2003) there are, however, important differences between the 
effects of U-II and AngII from those of ET-1. In fact, increased myocardial 
distensibility in response to ET-1 was observed only in acutely loaded cardiac muscles, 
which could justify why the effect of U-II was maintained in the presence of ET-1. 
The development of inhibitors of these neurohumoral systems has proven to be 
favourable in treating many cardiac diseases by inhibiting or reversing cardiovascular 
remodeling. Drugs like angiotensin converting enzyme inhibitors, angiotensin receptor 
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blockers, and aldosterone antagonists have been demonstrated to reduce mortality and 
morbidity in patients (Sleight 2002; Dimopoulos et al. 2004). Additionally, recent 
studies demonstrated, in a rat model of coronary artery ligation, that SB-611812, a 
specific UT receptor antagonist, significantly improved cardiac dysfunction (Bousette et 
al. 2006a) and promoted a reduction of cardiac remodeling (Bousette et al. 2006b). 
It is therefore reasonable to hypothesize that some cardiovascular effects could 
result from the interaction between different neurohumoral systems. From a 
physiopathological and clinical point of view, these results are potentially relevant, 
since the inhibition of a given neurohumoral system might also modulate the effects 
resulting from the activation of other systems. However, from the data presented, we 
cannot deduce the specific signaling pathways that underlie these results. Further 
investigations are needed to clarify this issue. 
Additionally, other weaknesses in this study must be pointed out. We cannot 
exclude the possibility that U-II exerts its effects through activation of AngII or ET-1 
receptors, or that both losartan and PD-145065 compound inhibit UT receptor. 
Therefore, both hypotheses would be a possible explanation for the results. Finally, 
when we added each or both of the antagonists of AngII or ET-1 systems, there is no 
direct evidence for the presence of AngII and ET-1 and activation of their respective 
receptors in the experimental preparation. 
In conclusion, the results of the present study suggested that in the rabbit the 
acute decrease of myocardial stiffness induced by U-II is mediated by AngII and ET-1 
systems. These results may contribute to a more complete understanding of the role of 
U-II in the acute modulation of myocardial function. They also show that neurohumoral 
systems might have potential points of interaction. Furthermore, this might add to our 
understanding of the pharmacologic effects of the receptor antagonists of these peptides. 
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FIGURE LEGENDS 
 
Figure 1. Effect of increasing concentrations of urotensin II (U-II; 10-8 to 10-6M) on 
active tension (AT), peak rates of tension rise and decline (dT/dtmax and dT/dtmin, 
respectively) (top) and muscle length (L/Lmax, bottom). Data are means ± SEM, 
expressed as percent variation from baseline. P< 0.05: α vs baseline, β vs 10-8M U-II, γ 
vs 10-7M U-II. 
 
Figure 2. Effect of increasing concentrations of urotensin II (U-II; 10-8 to 10-6M) on 
active tension (top) and muscle length (bottom, L/Lmax) in the absence (U-II) or presence 
of a selective AT1 receptor antagonist (losartan) (Los, 10-6M), a nonselective antagonist 
of ET-1 receptors (PD145065, 10-7M), or losartan (Los, 10-6M) plus PD-145065 (10-
7M). Data are means ± SEM, expressed as percent variation from baseline. P< 0.05: α vs 
baseline, β vs 10-8M U-II, γ vs 10-7M U-II, * vs U-II alone. 
 
Figure 3. Effect of increasing concentrations of urotensin II (U-II; 10-8 to 10-6M) on 
active tension (top) and muscle length (bottom, L/Lmax) in the absence (U-II) or presence 
of angiotensin II (AngII, 10-5M), or endothelin 1 (ET-1, 10-8M). Data are means ± SEM, 
expressed as percent variation from baseline. P< 0.05: α vs baseline, β vs 10-8M U-II, γ 
vs 10-7M U-II, * vs U-II alone. 
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